Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 65 points (-0.4%) at 16,380 as of Friday, Jan. 10, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,832 issues advancing vs. 1,123 declining with 123 unchanged. The Health Care sector currently sits up 0.4% versus the S&P 500, which is down 0.2%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 58.9%, Boston Scientific ( BSX), up 1.6%, AstraZeneca ( AZN), up 1.2% and Bristol-Myers Squibb Company ( BMY), up 0.9%. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 2.1%, Celgene Corporation ( CELG), down 2.1%, Amgen ( AMGN), down 2.0%, UnitedHealth Group ( UNH), down 1.8% and Humana ( HUM), down 1.6%. TheStreet would like to highlight 5 stocks pushing the sector higher today: 5. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $0.56 (1.5%) to $38.85 on average volume. Thus far, 905,220 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $38.40-$38.91 after having opened the day at $38.47 as compared to the previous trading day's close of $38.29. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $20.0 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 3.6% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.